The UK Biobank has unveiled research based on its collection of genetic data, a record which now includes the participation of over half a million people.
Founded nearly 20 years ago, the project is a large long-term study investigating the impact of genes and environmental factors in a wide range of diseases.
The repository of genetic information represents an invaluable resource for researchers looking to understand the causes of diseases, and potential medicines to address them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze